Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Crinetics Pharmaceuticals, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. Pacific Time [1] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [4] - The company has a deep pipeline of over 10 disclosed programs, including late-stage candidates such as atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors and other solid tumors [4] - Additional discovery programs target various endocrine conditions, including neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [4]